Romidepsin Patent Expiration
Romidepsin was first introduced by Bristol-Myers Squibb Co
Romidepsin Patents
Given below is the list of patents protecting Romidepsin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Istodax | US7608280 | Method of producing FR901228 |
Aug 22, 2021
(Expired) | Bristol-myers |
| Istodax | US7611724 | Method of producing FR901228 |
Aug 22, 2021
(Expired) | Bristol-myers |
| Istodax | US4977138 | FR901228 substance and preparation thereof |
Aug 22, 2013
(Expired) | Bristol-myers |
Romidepsin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Romidepsin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | University of Michigan Rogel Cancer Center | NA |
TERMINATED
(Apr 1, 2026)
| PHASE1, PHASE2 |